ClinicalTrials.gg
Active, not recruitingNCT07543367Updated Nov 5, 2026

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

An interventional study of Stentrode in Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis) and Motor Neuron Disease, sponsored by Synchron, Inc.. Active, not recruiting at 5 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionAmyotrophic Lateral SclerosisRegistry: Nervous System DiseasesReclassifiedWhy we changed it
Registry
Nervous System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Amyotrophic Lateral Sclerosis
Why
  1. The study's listed conditions name Amyotrophic Lateral Sclerosis, a narrower term within Nervous System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Synchron, Inc. · Not applicable, Interventional, and Other

How we know

Updated Nov 5, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
246th of 307
10 · median 33
Started
2026
with 32 others
No phase
82 of 440
32 open now
Primary completion
2027-01
later than 36 of 128 live
Registered
425th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 246th largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 82 with no phase, reaches primary completion later than 36 of the 128 other live ones, and was the 425th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

Read the detailed description

The Synchron BCI motor neuroprosthesis is an implanted brain-computer interface indicated for individuals with bilateral upper-limb motor impairment, such as Amyotrophic Lateral Sclerosis (ALS). The Synchron BCI is intended to replace the function of motor neurons by detecting, translating and transmitting motor-related brain signals to restore clinically meaningful control of digital devices.

03

Conditions studied

  • Neurological Disorder
  • ALS (Amyotrophic Lateral Sclerosis)
  • Motor Neuron Disease
  • ALS - Amyotrophic Lateral Sclerosis
  • ALS

Browse trials for

04

In context

Amyotrophic Lateral Sclerosis Reclassified

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

This study's planned enrollment of 10 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.

Browse Amyotrophic Lateral Sclerosis studies →

Lead sponsor

Synchron, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Compared within Amyotrophic Lateral Sclerosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide to participate in the study.
  • Diagnosis of ALS, with bilateral upper-limb paresis.
  • ALS must be to treatment and have been present for a minimum of six months.
  • Aged 22 years or older.
  • greater than 12 months post-implantation.
  • Preserved precentral gyrus assessed using CT.
  • Suitable vascular anatomy assessed using CT venography.
  • Suitable anatomy for subcutaneous pocket creation.
  • Able to undergo anesthesia.
  • Willing and able to comply with all requirements, including clinical testing visits and training visits in the home.
  • Caregiver(s) willing and able to facilitate study visits, including visits to the study site and in the home, and BCI use outside of study visits (e.g., device charging).
  • Patient and caregiver fluent in English.
  • Suitable home environment for BCI training.

Exclusion criteria

Exclusion Criteria:

  • Active infection or unexplained fever in the 48 hours prior to .
  • Major psychiatric disorder that may adversely impact the participant's safety or study compliance, including severe depression, psychotic features, personality disorder, severe emotional lability, or substance abuse.
  • Diagnosis of ALS-FTD or another dementia.
  • Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).
  • Known allergy to patient-contacting materials included in the implanted device.
  • to angiographic imaging or iodine contrast media.
  • History of central venous sinus thrombosis.
  • Recent history of new venous thromboembolic event (in the 6 months prior to implant), recurrent history of venous thromboembolic disease, or hypercoagulable state.
  • Contraindication to antithrombotic therapy.
  • Participant is at substantially increased risk of infection, including status, recurrent or chronic infection, or poorly controlled diabetes mellitus.
  • Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.
  • Pregnant or breast feeding.
  • Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.
  • Any other disease or disorder that could significantly affect participation in the study. Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    Single Arm

    Device: Stentrode

    Device: Stentrode

Interventions

  • DeviceStentrode

    The Stentrode is an endovascular electrode array that senses electrical signals from the sensorimotor cortices.

07

What researchers measure

Primary outcomes

  1. Device-related serious adverse events up to 180 days after implant

    Time frame: 6 Months

Secondary outcomes

  1. Device-related serious adverse events up to 1 year after implant

    Time frame: 12 Months

  2. Target vessel patency assessed using CT venography at 180 days and 364 days after implant

    Time frame: 6 Months and 12 Months

  3. Device migration assessed using CT images at 180 days and 365 days after implant

    Time frame: 6 Months and 12 Months

Other outcomes

  1. Time in days from implant to device activation

    Time frame: Number of days from device implant to device activation, up to 12 months after implant

  2. Time in days from device activation to successful demonstration of motor signal transmission.

    Time frame: Number of days from device activation to successful demonstration of motor signal transmission, up to 12 months after implant.

  3. Stability of recorded Synchron BCI signal up to 3 years after device implant

    Time frame: 12 Months

  4. Synchron BCI use up to 1 year after device implant

    Time frame: 12 Months

08

Study locations

5 sites
09

References and documents

Individual participant data

Plan to share: No — There are no plans at this time.

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 154 interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 60. This study's planned 8 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → May 2026, on Oct 21, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Jan 2027, on Nov 5, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2029 → Jul 2029, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
May 7, 2026was Apr 2026
Primary completionEst.
Jan 2027was Jun 2027
CompletionEst.
Jul 2029was Dec 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Start date
Apr 2026→May 7, 2026 (actual)
Oct 21, 2026
Primary completion
Jun 2027→Jan 2027
Nov 5, 2026
Study completion
Dec 2029→Jul 2029
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 2027→Jan 2027
    Study completion Dec 2029→Jul 2029
    + 3 other changes: verification date, site details and contact details
  2. Oct 21, 2026
    Start date Apr 2026→May 7, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07543367
Lead sponsor
Synchron, Inc.
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 7, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion